Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Psyence Group Inc (PSYG.CN)

Psyence Group Inc (PSYG.CN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Psyence Group Inc 121 Richmond Street West Penthouse Suite, 1300 Toronto ON M5H 2K1 CAN

https://www.psyence.com P: 416-477-1708

Sector:

N/A

Description:

Psyence Group Inc is a life science biotechnology company focused on the research, cultivation, and production of psychedelics and nature-based compounds to treat psychological trauma in the context of palliative care and support of mental wellness. It is involved in cultivating and exporting psilocybin mushrooms to the legal medical and research markets; developing drugs in the field of palliative care; and offering a range of non-psilocybin containing functional mushroom nutraceutical products called Goodmind, designed to enhance mental capacity and the body's ability to adapt to stress. The group operates in two segments: clinical trial activities and non-clinical trial activities. Geographically, it has a presence in Canada, the USA, Southern Africa, and the British Virgin Islands.

Key Statistics

Overview:

Market Capitalization, $K 1,877
Shares Outstanding, K 15,638
Annual Sales, $ 0 K
Annual Net Income, $ -30 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -70 K
60-Month Beta 3.65

Growth:

1-Year Return -60.00%
3-Year Return -92.00%
5-Year Return 0.00%
5-Year Revenue Growth 0.00%

Per-Share Information:

Most Recent Earnings 0.00 on 11/28/25
Next Earnings Date N/A
Earnings Per Share ttm -1.01
EPS Growth vs. Prev Year -80.46%
Dividend Payout Ratio 0.00%
Most Recent Split 1-15 on 04/23/25

PSYG.CN Ratios

Ratio
Price/Earnings ttm N/A
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % N/A
Return-on-Assets % -631.21%
Profit Margin % 0.00%
Debt/Equity N/A
Price/Sales N/A
Price/Book 2.23
Book Value/Share 0.05
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar